■神经表皮生长因子样1膜性肾病(NELL1MN)与各种继发性病因有关。然而,以往关于这些关联的频率及其对结局的影响的研究有限.我们报告了NELL1MN患者的大型多机构系列,重点是次要关联,病理结果,以及它们对结果的影响。
■我们回顾性回顾了来自3个机构的NELL1MN的临床病理特征,并分析了与预后的临床和组织学关联。
■在70名患者中,53%为男性,中位年龄为66岁;中位蛋白尿为5.9g/d。NELL1MN与硫辛酸(36%)有关,重度非甾体抗炎药(NSAID)使用(27%),自身免疫性疾病(23%),恶性肿瘤(最近10%,23%任何),汞暴露(1%),和11%没有已知的次要关联。在中位随访11个月时,72%达到完全或部分缓解。硫辛酸相关NELL1MN患者的缓解率为91%,随访时间≥6个月。在多变量分析中,原发性NELL1MN(调整比值比[OR]:19.7,P=0.01)和肾小管萎缩和间质纤维化(IFTA)程度增加(调整OR1.1,P=0.01)的患者不太可能达到任何缓解,而完全缓解(CR)与硫辛酸使用(校正后OR:10.9,P=0.04,95%置信区间[CI]:1.2-100)和较低IFTA程度(校正后OR:0.79,P=0.16,95%CI:0.66-0.96)相关.
■我们的发现加强了硫辛酸与NELL1MN之间的联系。此外,我们的研究结果表明,停用硫辛酸无免疫抑制应被视为一线治疗.
UNASSIGNED: Neural epidermal growth factor like 1 membranous nephropathy (
NELL1 MN) is associated with various secondary etiologies. However, previous studies on the frequency of these associations and their impact on outcomes are limited. We report a large multiinstitutional series of patients with NELL1 MN with a focus on secondary associations, pathology findings, and their impact on outcome.
UNASSIGNED: We retrospectively reviewed clinicopathologic features of NELL1 MN from 3 institutions and analyzed clinical and histologic associations with outcome.
UNASSIGNED: Of 70 patients, 53% were male with a median age of 66 years; median proteinuria was 5.9 g/d.
NELL1 MN was associated with lipoic acid (36%), heavy nonsteroidal antiinflammatory drug (NSAID) use (27%), autoimmune disease (23%), malignancy (10% recent, 23% any), mercury exposure (1%), and 11% had no known secondary association. At median follow-up of 11 months, 72% achieved complete or partial remission. Remission rate was 91% in patients with lipoic acid-associated
NELL1 MN and ≥6 months of follow-up. On multivariable analyses, patients with primary
NELL1 MN (adjusted odds ratio [OR]: 19.7, P = 0.01) and increasing degree of tubular atrophy and interstitial fibrosis (IFTA) (adjusted OR 1.1, P = 0.01) were less likely to achieve any remission, whereas complete remission (CR) was associated with lipoic acid use (adjusted OR: 10.9, P = 0.04, 95% confidence interval [CI]: 1.2-100) and lesser degrees of IFTA (adjusted OR: 0.79, P = 0.16, 95% CI: 0.66-0.96).
UNASSIGNED: Our findings strengthen the association between lipoic acid and
NELL1 MN. Furthermore, our findings suggest that discontinuation of lipoic acid without immunosuppression should be considered as the first-line treatment.